Oculopharyngeal muscular dystrophy: potential therapies for an aggregate-associated disorder

The International Journal of Biochemistry & Cell Biology
Janet E DaviesDavid C Rubinsztein

Abstract

Oculopharyngeal muscular dystrophy (OPMD) is a late-onset, autosomal dominant disease caused by the abnormal expansion of a polyalanine tract within the coding region of poly(A) binding protein nuclear 1 (PABPN1). The resultant mutant PABPN1 forms aggregates within the nuclei of skeletal muscle fibres. The mechanism by which the polyalanine expansion mutation in PABN1 causes disease is unclear. However, the mutation is thought to confer a toxic gain-of-function on the protein. Despite controversy over the role of aggregates, it has been consistently shown that agents that reduce aggregate load in cell models of OPMD also reduce levels of cell death. Recently generated animal models of OPMD will help elucidate the mechanism of disease and allow the trial of potential therapeutics. Indeed, administration of known anti-aggregation drugs attenuated muscle weakness in an OPMD mouse model. This suggests that anti-aggregation therapies may be beneficial in OPMD.

References

Mar 7, 2003·The Canadian Journal of Neurological Sciences. Le Journal Canadien Des Sciences Neurologiques·Xueping Fan, Guy A Rouleau
Apr 20, 2004·FEBS Letters·Anubhav AroraChan Beum Park
May 26, 2004·Biochimica Et Biophysica Acta·Uwe Kühn, Elmar Wahle
May 27, 2005·Current Opinion in Genetics & Development·Andrea Albrecht, Stefan Mundlos
Aug 23, 2005·Proteins·Leonid M ShinchukDaniel A Kirschner
Sep 6, 2005·Human Molecular Genetics·Zdenek BergerCahir J O'Kane
Dec 24, 2005·Human Molecular Genetics·Zdenek BergerDavid C Rubinsztein

❮ Previous
Next ❯

Citations

Sep 15, 2006·Nature Reviews. Molecular Cell Biology·Kay E Davies, Kristen J Nowak
Sep 2, 2010·Proceedings of the National Academy of Sciences of the United States of America·Sohini ChakraborteeAlan Tunnacliffe
Dec 26, 2009·Human Molecular Genetics·Luciano H ApponiGrace K Pavlath
Jan 5, 2011·Human Molecular Genetics·Janet E Davies, David C Rubinsztein
Jun 4, 2010·Science Translational Medicine·Janet E DaviesDavid C Rubinsztein
Jun 28, 2006·Journal of Medical Genetics·J E Davies, D C Rubinsztein
Sep 21, 2013·Drug Discovery Today. Technologies·Aymeric Chartier, Martine Simonelig
Mar 17, 2010·Brain Research·Karen Anthony, Jean-Marc Gallo
Aug 1, 2009·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Thomas B NicholsonStéphane Richard
Dec 23, 2008·Journal of the Neurological Sciences·Hung-Chou KuoChin-Chang Huang
Mar 28, 2008·Experimental Cell Research·Arnaud F KleinBernard Brais
Sep 15, 2007·Journal of the Neurological Sciences·Zhi-Fang LiG Diane Shelton
Oct 27, 2011·Wiley Interdisciplinary Reviews. RNA·Keith A HansonRandal S Tibbetts
Oct 19, 2006·The International Journal of Biochemistry & Cell Biology·Tiziana BachettiIsabella Ceccherini
Dec 19, 2014·Frontiers in Aging Neuroscience·Luigi FormicolaDavid A Sassoon
Apr 1, 2017·Nature Communications·A MalerbaG Dickson
Mar 18, 2017·The Journal of Physiology·Maricela García-CastañedaGuillermo Avila
Jan 8, 2008·Human Molecular Genetics·Janet E DaviesDavid C Rubinsztein
Dec 20, 2007·The Journal of Pharmacology and Experimental Therapeutics·Mounir ErramiHarold R Garner
Nov 7, 2019·International Journal of Molecular Sciences·Daniela Gois BeghiniAndrea Henriques-Pons
Mar 17, 2015·Intrinsically Disordered Proteins·Vladimir N Uversky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis